About Scott Glenn
Form D filings for Evida Biosciences in 2024 list Scott Glenn as director.
Form D filings also name Scott Glenn as a director at Mirador Therapeutics and GLO Pharma.
Scott Glenn first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Scott Glenn in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Scott Glenn works with at each company, as listed on that company's latest Form D.
Evida Biosciences Inc. · Form D, Oct 11, 2024
MW
Michael Walsh
President, Secretary and Chief Financial Officer, director
LO
Lauren Otsuki
Director
RB
Rolf Benirschke
Director
SW
Shierley Widjaja
Director
DW
David Wrigley
Director
BD
Brian Feagan, M.D.
Director
Mirador Therapeutics, Inc. · Form D, Apr 3, 2024
PB
Paul Berns
Director
JP
Joseph Papa
Director
MM
Mark McKenna
Executive officer and director
KB
Kristina Burow
Director
VB
Vika Brough
Executive officer
DD
David Bonita, M.D.
Director
TA
Timothy Andrews
Secretary
GLO Pharma, Inc. · Form D/A, Apr 3, 2023
MB
Marla Beck
Director
NQ
Nicole Quinn
Director
DQ
Dayna Quanbeck
Director
BS
Brent Saunders
Director
VG
Vimla Black-Gupta
President and Chief Executive Officer, director
LO
Lauren Otsuki
Executive officer and director